Back to Search
JOHN STRAUGHN, M.D.
M.D.
Specialist
NPI: 1508865957Individual
Specialties, Licenses & Credentials
Research & Publications (20)
Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model.
PMID 16271751·Gynecol Oncol·2006
7-preclinical
The use of adjuvant radiation therapy in patients with intermediate-risk Stages IC and II uterine corpus cancer: a patient care evaluation study from the American College of Surgeons National Cancer Data Base.
PMID 16198401·Gynecol Oncol·2005
4-observational
A cost-effectiveness analysis of screening strategies for cervical intraepithelial neoplasia.
PMID 15874873·J Low Genit Tract Dis·2004
8-other
Stage IC adenocarcinoma of the endometrium: survival comparisons of surgically staged patients with and without adjuvant radiation therapy.
PMID 12713994·Gynecol Oncol·2003
4-observational
Conservative management of stage I endometrial carcinoma after surgical staging.
PMID 11812074·Gynecol Oncol·2002
8-other
Predictors of outcome in small cell carcinoma of the cervix--a case series.
PMID 11606074·Gynecol Oncol·2001
6-review
A patient presenting with a pelvic mass, elevated CA-125, and fever.
PMID 10831363·Gynecol Oncol·2000
5-case
Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer.
PMID 19232697·Gynecol Oncol·2009
6-review
The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer.
PMID 19447480·Gynecol Oncol·2009
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2006 BROOKWOOD MEDICAL CTR DR, SUITE 202
BIRMINGHAM, AL 35209 - Phone
- (205) 397-8850
Quick Facts
- NPI
- 1508865957
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile